Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 135 Small Cell Lung Carcinoma 51 Lung Neoplasms 45 Melanoma 15 Carcinoma, Renal Cell 14 Carcinoma, Transitional Cell 10 Stomach Neoplasms 9 Neoplasms 9 Head and Neck Neoplasms 9 Carcinoma, Hepatocellular 9 Mesothelioma, Malignant 8 Colorectal Neoplasms 8 Urinary Bladder Neoplasms 7 Triple Negative Breast Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Breast Neoplasms 6 Uterine Cervical Neoplasms 5 Neoplasm Metastasis 5 Kidney Neoplasms 5 Carcinoma, Merkel Cell 5 Thoracic Neoplasms 4 Carcinoma, Neuroendocrine 4 Small Cell Lung Cancer Extensive Stage 3 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Mesothelioma 3 Lung Diseases 3 Gastrointestinal Neoplasms 3 Esophageal Neoplasms 3 Brain Neoplasms 3

Interventions

atezolizumab 1 Temozolomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Small Cell Lung Cancer Recurrent × atezolizumab × Thoracic × Clear all

NCT03262454 2022-04-06

Atezolizumab

National Cancer Center, Korea

Phase 2 Unknown

Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡